Study of INCB086550 in Select Solid Tumors

Summary

An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors

Timeline

Start

2021-09-02

Primary completion

2024-03-26

Completion

2024-03-26

Outcome

Outcome not reported

Stopped (Business): “Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile.”

Drugs

Indications